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2004a, 2004b). Like the L I domain, the 2 I-like domain
contains a MIDAS that plays a key role in its function.
Although there are no overall structures for integrins
that contain I domains, rapid progress has recently been
made in understanding the structural basis for regulation
Azucena Salas,1 Motomu Shimaoka,2 Avi N. Kogan,3
Charlotte Harwood,1 Ulrich H. von Andrian,1
and Timothy A. Springer1,*
The CBR Institute for Biomedical Research
1Department of Pathology
of ligand binding in integrins that lack I domains. In these2 Department of Anesthesia
integrins, the  subunit I-like domain and the -subunit3 Program in Biophysics
-propeller domain constitute the ligand binding siteHarvard Medical School
(Takagi et al., 2003; Xiong et al., 2002; Yahalom et al.,200 Longwood Avenue
2002). A crystal structure for most of the extracellularBoston, Massachusetts 02115
domains of integrin V3 revealed an unexpected overall
V-shaped organization, in which the ligand binding do-
mains in the headpiece are bent toward the cell mem-Summary
brane by extensive interactions with tailpiece domains
(Takagi et al., 2002; Xiong et al., 2001). The extremeIn vivo, 2 integrins and particularly L2 (LFA-1) ro-
bend in the  and  subunits occurs at a location termedbustly support firm adhesion of leukocytes, but can
the “genu.” Based on evidence from the NMR structurealso cooperate with other molecules in supporting roll-
of 2 subunit I-EGF domains (Beglova et al., 2002), to-ing adhesion. Strikingly, a small molecule / I-like
gether with mapping of activation-dependent or activa-allosteric antagonist, XVA143, inhibits LFA-1-depen-
tion-inducing mAbs and sites of interaction with  thatdent firm adhesion, while at the same time it enhances
constrain 2 integrins in the resting conformation (Lu etadhesion in shear flow and rolling both in vitro and
al., 2001a; Zang and Springer, 2001), the bent conforma-in vivo. XVA143 appears to induce the extended con-
tion was proposed to represent a low-affinity state offormation of integrins as shown by increased acti-
the integrin, and a switchblade-like opening was pro-vation epitope exposure. Fab to the 2 I-like domain
posed to occur upon activation. Indeed, EM and muta-converts firm adhesion to rolling adhesion, but does
tional studies of integrins V3 and 51 have directlynot enhance adhesion. ResidueL-Glu-310 in the linker
demonstrated at least three distinct conformationalfollowing the I domain is critical for communication
states (Takagi et al., 2002, 2003). These correspond toto the 2 I-like domain, rolling, integrin extension, and
the bent conformation seen in the crystal structure thatactivation by Mn2 of firm adhesion. The results dem-
has low affinity for ligand (Figure 1F), and two extendedonstrate the importance of integrin extension in rolling,
conformations that differ in the angle between the I-likeand suggest that rolling and firm adhesion are medi-
and hybrid domains (Figures 1G and 1H). The extendedated by extended conformations of L2 that differ in
conformations with the open (Figure 1H) and closedthe affinity of the L I domain for ICAM-1.
(Figure 1G) headpieces appear to have high and interme-
diate affinity for ligand, respectively. Recent mutagene-Introduction
sis, epitope mapping, and solution X-ray scattering
studies have supported integrin extension and hybridIntegrins are a family of heterodimeric receptors that
domain swing-out in the open headpiece conformationuse bidirectional (inside-out and outside-in) signaling to
(Luo et al., 2003b; Mould et al., 2003a, 2003b) whileintegrate the intracellular and extracellular environ-
ruling out an alternative model of headpiece separation
ments. Some integrins contain an inserted (I) domain in
(Luo et al., 2003a; Mould et al., 2003b).
their  subunits, including LFA-1 (integrin L2) (Hum- The integrin L2 appears to undergo similar confor-phries, 2000; Shimaoka et al., 2002). LFA-1 binds IgSF mational transitions, as shown with epitopes that be-
cell surface molecules known as intercellular adhesion come exposed upon LFA-1 activation and map to 2molecules (ICAMs) and functions in lymphocyte recogni- I-EGF domains 2 and 3 (Beglova et al., 2002) (Figures
tion of other cells and in leukocyte trafficking between 1A–1E). Work with a class of small molecules termed
blood, tissue, and lymph (Springer, 1994). The ligand / I-like allosteric antagonists also suggests analogous
binding site of LFA-1 is wholly contained within the L conformational changes in L2. These compounds bind
I domain (Lu et al., 2001b; Shimaoka et al., 2001, 2003b). to the MIDAS of the 2 I-like domain, and also to the
One- and two-turn axial displacements in the C-terminal L-subunit (Shimaoka et al., 2003a). They structurally
direction of the L I domain 7-helix are linked to re- resemble small molecule RGD-based antagonists in
arrangements around the ligand binding site at the metal containing an absolutely required carboxyl group that
ion dependent adhesion site (MIDAS) and to increases is thought to bind to the 2 I-like domain MIDAS. The /
in affinity for ICAM-1 of up to 10,000-fold (Huth et al., I-like allosteric antagonists, like RGD-based / I-like
2000; Shimaoka et al., 2003b). The I-like domain in the competitive antagonists, also appear to bind across the
integrin 2 subunit undergoes conformational changes interface between the -subunit -propeller and -sub-
during activation that allosterically regulate binding unit I-like domains (Shimaoka et al., 2003a). Further-
through the L I domain (Lu et al., 2001c; Yang et al., more, both classes of compounds induce the extended
integrin conformation, as shown by exposure of activa-
tion epitopes (Kouns et al., 1992; Shimaoka et al., 2003a;*Correspondence: springeroffice@cbr.med.harvard.edu
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Figure 1. Conformational States for Integrins and Structure of L2 Antagonists
(A–E) Model for L2 integrin activation. The models for all of the extracellular domains except for the I domain (Springer, 2002) are based on
conformational states of V3 defined by negative stain electron microscopy (Takagi et al., 2002), crystallography (Xiong et al., 2002), NMR
(Beglova et al., 2002), and mapping of activation epitopes (Lu et al., 2001a, 2001c). The L I domain is a cartoon based on crystal structures
(Shimaoka et al., 2003b). The I domain is joined at the point of its insertion in the -propeller domain but its orientation is arbitrary; the I
domain is shown at slightly larger scale for emphasis. The C-terminal I domain -helix is represented by a red cylinder, and L Glu-310 in the
linker as a blue sphere. The positions of the epitope recognized by the TS1/18 Fab used here, and activation epitopes, are circled. Epitopes
are circled only in the conformations in which they are thought to be exposed. (A) Bent conformation with low affinity. (B and C) LFA-1 with
a closed headpiece and closed I domain in partially (B) or fully (C) extended states. (D) Extended conformation with open headpiece, and
closed I domain, in the presence of XVA143, represented by three red spheres. (E) Extended conformation with open headpiece and open
I domain.
(F–H) Model for V3 integrin activation, with at least three conformations of the extracellular domain (Takagi et al., 2002). (F) Bent, low-affinity
conformation. (G) Extended conformation with closed headpiece. (H) Extended conformation with open headpiece. (I) Chemical structures of
small molecule L2 antagonists used in this study.
Takagi et al., 2002), and for V3, by direct electron mi- 7-helix of the L I domain and stabilize it in the closed
conformation (Kallen et al., 1999; Lu et al., 2001b; Weitz-croscopic observation (Takagi et al., 2002). By contrast,
 I allosteric antagonists of L2, which bind under the Schmidt et al., 2001), stabilize the bent conformation,
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as shown by suppression of epitope induction by Mn2 importance of integrin extension or conformational
(Shimaoka et al., 2003a; Woska et al., 2001). breathing in regulating rolling, and the interrelationship
L2 and the other 2 integrins are far more facile in in L2 between global conformation and the conforma-
supporting firm adhesion than rolling adhesion. In many tion of the L I domain, the 2 I-like domain, and the
in vitro and in vivo systems in which 2 integrins mediate coupling between these domains. We not only demon-
firm adhesion and selectins mediate tethering and rolling strate the importance of integrin extension in rolling,
adhesion, 2 integrins are not seen to mediate tethering but also make the surprising observation that / I-like
in shear flow or rolling (Lawrence and Springer, 1991; allosteric antagonists markedly enhance or induce roll-
von Andrian et al., 1991). The 4 integrins have been ing adhesion while inhibiting firm adhesion.
known for some time to mediate rolling as well as firm
adhesion (Alon et al., 1995; Berlin et al., 1995), although Results
they do not support rolling as efficiently as selectins (de
Chateau et al., 2001). Nonetheless, in vivo studies have An / I-like Allosteric Antagonist Blocks Activation-
suggested for some time that while 2 integrins cannot Dependent Adhesion and in Contrast Enhances
on their own mediate rolling, they can contribute to roll- Rolling Adhesion on ICAM-1
ing together with selectins or 4 integrins. Thus, when In conditions in which L2 is in a low-affinity conforma-
2 integrin function is blocked in vivo, and particularly tion, such as in Ca2/Mg2, binding to soluble ICAM-1,
when 2 integrins or L2 are blocked or eliminated to- even as a multimeric complex of ICAM-1-Fcwith FITC-
gether with one or more selectins or 4 integrins, they anti-IgA, is weak (Figure 2A). Activation, for example by
can be seen to contribute to the accumulation of rolling Mg2/EGTA or Mn2, is required to convert L2 to a
cells, the stability of rolling, and the velocity of rolling form that can bind soluble, multimeric ICAM-1 with high
cells in inflamed tissues (Forlow and Ley, 2001; Forlow affinity (Figure 2A). However, appropriate conditions can
et al., 2000; Henderson et al., 2001; Jung et al., 1998; be found where L2 transfectants in Ca2/Mg2 bind
Perry and Granger, 1991). By contrast, LFA-1 has been to ICAM-1 substrates in shear flow at 0.3–0.4 dyn/cm2
shown not to contribute to lymphocyte rolling in the high (Figure 2B) as previously described (Salas et al., 2002;
endothelial venules (HEV) of noninflamed lymph nodes Sigal et al., 2000). Once cells are bound, their interac-
(Warnock et al., 1998). In vitro, LFA-1 can mediate teth- tions with ICAM-1 substrates in Ca2/Mg2 are relatively
ering in flow of leukocytes to ICAM-2 on platelets in the shear resistant, with cells continuing to roll or adhere
absence of selectin-mediated interactions (Weber and at shear stresses ranging from 1 to 8 dyn/cm2 (Figure
Springer, 1997). Moreover, special attention to the way 2B; Salas et al., 2002). The fraction of cells that roll
in which ICAM-1 is coupled to the substrate, and to the increases markedly with increasing shear (Figure 2B).
type of LFA-1 bearing cell that is used, enables rolling In contrast, in the presence of Mg2/EGTA (Figure 2E)
solely through L2 heterodimers to be detected in vitro or Mn2 (data not shown), most cells adhere firmly to
(Salas et al., 2002; Sigal et al., 2000). Surprisingly, the the ICAM-1 substrate and remain attached even after
wild-type L I domain expressed in isolation from other shear is increased to 16 dyn/cm2.
integrin domains by fusing its C terminus to an artificial
Two classes of small molecule antagonists were used
membrane anchor supports rolling on ICAM-1 much
to probe the effect of the overall conformation of L2more efficiently than L2 heterodimers (Knorr and Dus- on its ability to mediate rolling.  I allosteric antagonists,
tin, 1997; Salas et al., 2002). Is an isolated, L I domain represented here by BIRT377 (Figure 1I), bind in a hydro-expressed on the cell surface in a better orientation to
phobic pocket under the C-terminal -helix of the I do-mediate tethering and rolling on ICAM-1 than a bent
main, stabilize the I domain in the closed, low-affinity
L2 heterodimer? Isolated I domains locked in the open conformation (Kallen et al., 1999; Last-Barney et al.,conformation with a disulfide-bond mediate firm adhe-
2001; Liu et al., 2001; Weitz-Schmidt et al., 2001), andsion (Salas et al., 2002), as do L2 integrins activated
also inhibit activation epitope exposure in L2 (Shi-by Mn2, activating antibodies, or physiologic activating
maoka et al., 2003b; Woska et al., 2001), i.e., stabilizestimuli (Campbell et al., 1998; Lawrence et al., 1995;
the bent conformation (Figure 1A). / I-like allostericLawrence and Springer, 1991; Salas et al., 2002; Sigal
antagonists, represented here by XVA143 (Figure 1I),et al., 2000; von Andrian et al., 1991). However, the ability
bind to the MIDAS of the 2 I-like domain, as well as toof L2 and other 2 integrins to support rolling in vivo
a region of the L subunit that does not include the Iraises the intriguing possibility that rolling might be me-
domain (Shimaoka et al., 2003a; Welzenbach et al.,diated by an intermediate conformation of L2, with an
2002). / I-like allosteric antagonists were identified byextended conformation but with the I domain in a low
their ability to inhibit high-affinity binding of L2 toor intermediate affinity state, corresponding approxi-
ICAM-1 (Fotouhi et al., 1999; Gadek et al., 2002), asmately to the conformation depicted in Figures 1B
subsequently confirmed (Shimaoka et al., 2003a; Wel-and 1C.
zenbach et al., 2002). / I-like allosteric antagonistsHow the overall conformation of L2 relates to its
bind to a critical interface for relaying conformationalability to support rolling adhesion remains to be eluci-
signals within L2 (Shimaoka et al., 2003a). By bindingdated. The greater height above the cell surface of the
to the 2 I-like domain MIDAS, they stabilize the I-likeheadpiece in the extended conformation, and its altered
domain in the active conformation and induce the ex-orientation, appear more favorable for ligand encounter.
tended conformation of L2 as shown by exposure ofAlthough both L2 and 4 integrins can mediate rolling,
activation epitopes, while blocking activation of the Lnothing is currently known about the global conforma-
I domain by the 2 I-like domain (Figure 1D) (Shimaokation of these integrins during rolling, or how overall con-
formation influences rolling. Here, we demonstrate the et al., 2003a).
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Figure 2. Effect of XVA143 on Binding to ICAM-1
(A) K562 cells expressing L2 were incubated with XVA143 in the presence of the indicated divalent cations. Binding of multimeric, soluble
ICAM-1 was determined using flow cytometry and expressed as specific mean fluorescence intensity (MFI).
(B) L2 K562 cells were prepared in Buffer A/1 mM Ca2/1 mM Mg2 containing DMSO, 1 M XVA143, or 10 M LFA703. Cells were immediately
infused into a flow chamber with ICAM-1-Fc immobilized on the lower wall. The number of firmly adherent or rolling cells was determined
for each shear stress interval. Bars represent the average  SEM of three to five independent experiments.
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If integrin extension is important in supporting rolling, Dose Dependence of the Effect of XVA143 on Rolling
Stability and Exposure of Activation Epitopeswhereas the high-affinity conformation of theL I domain
is not, then / I-like allosteric antagonists should have The IC50 values for inhibition by XVA143 of binding of
soluble, multimeric ICAM-1 varied depending on the ac-the paradoxical effect of enhancing rolling adhesion
through L2. Indeed, in Ca2/Mg2, XVA143 markedly tivating divalent cation conditions. XVA143 was most
potent against the weakest activator (2 mM Mg2/1 mMincreased the total number of L2 transfectants that
accumulated at 0.3 dyn/cm2, and remained adherent EGTA, IC50 103 nM) and least potent against the
strongest activator (1 mM Mn2, IC50 0.3 nM) (Figureat 0.4 to 16 dyn/cm2 (Figure 2B). Furthermore, XVA143
increased the total number of cells that rolled, and de- 2A). The IC50 value for 10 mM Mg2/1 mM EGTA was
intermediate (102 nM). All of these IC50 values for inhi-creased the number of cells that were firmly adherent,
at all wall shear stresses in Ca2/Mg2 (Figure 2B). The bition of soluble multimeric ICAM-1 binding are in the
subnanomolar range. By contrast, in shear flow adhe-increase in rollingly adherent cells was particularly
marked at 2 to 16 dyn/cm2 (Figure 2B). The agonistic sion assays in Mg2/EGTA, 500 nM to 1 M concentra-
tions were required for inhibition of firm adhesion, andeffect in shear flow of XVA143 was further verified in
accumulation assays (Figure 2C). Accumulation at all for stimulation of rolling adhesion (Figure 2E). This differ-
ence may reflect a higher affinity of XVA143 for activatedwall shear stresses tested, 0.4, 0.6, and 0.8 dyn/cm2,
was enhanced by XVA143. In contrast, the  I allosteric receptors than for resting receptors, as demonstrated
for / I-like competitive antagonists of integrin IIb3antagonists LFA703 and BIRT377, which stabilize the
closed conformation of the I domain, and the overall (Bednar et al., 1998).
We hypothesized that exposure of activation epitopesbent conformation of L2 (Shimaoka et al., 2003a)
greatly decreased the number of interacting cells (Figure and stimulation of rolling adhesion in Ca2/Mg2 would
each involve binding of XVA143 to the low-affinity resting2B; data not shown) (Salas et al., 2002).
Although 2 integrins clearly contribute to leukocyte receptor, and therefore should occur in similar concen-
tration ranges. Increasing concentrations of XVA143rolling in inflamed vessels in vivo (Forlow and Ley, 2001;
Forlow et al., 2000; Henderson et al., 2001; Jung et al., markedly stabilized rolling interactions, as shown by a
higher number of rolling cells (Figure 3A) and slower1998; Perry and Granger, 1991), rolling by peripheral
blood cells on ICAM-1 substrates has not previously rolling velocities (Figure 3B). The effect of XVA143 began
at a concentration of about 10 nM and was maximal atbeen demonstrated in vitro. Indeed, under control condi-
tions we failed to detect rolling by peripheral blood lym- about 1 M. The dose responses were examined for
exposure of activation epitopes recognized by mAbs tophocytes (PBL) on ICAM-1 substrates (Figure 2D), con-
sistent with the markedly lower expression of LFA-1 different L2 extracellular domains. mAb KIM127 maps
to residues in I-EGF domain 2 of the 2 subunit (Beglovaon PBL than K562 transfectants (not shown). However,
XVA143 treatment induced readily detectable tethering et al., 2002; Lu et al., 2001a; Robinson et al., 1992). mAb
m24 maps to residues that locate near the top of the 2in shear flow and rolling adhesion of PBL on ICAM-1
substrates (Figure 2D). By contrast, the  I antagonist subunit I-like domain, not far from its MIDAS (Lu et al.,
2001c). The exposure of the KIM127 and m24 epitopesBIRT377 did not induce rolling adhesion (Figure 2D). In
Mg2/EGTA (Figure 2E) and Mn2 (not shown), LFA-1 by XVA143 followed a similar dose-response as for sta-
bilization of rolling, with the largest increase in the rangebearing cells develop firm adhesion to ICAM-1 sub-
strates, with hardly any cells rolling. Addition of increas- of 10 nM to 1 M (Figure 3C). The EC50 values for stabili-
zation of rolling adhesion and induction of activationing concentrations of XVA143 resulted in a decreasing
number of firmly adherent cells and an increasing num- epitopes each occurred within the range of 10 to 100
nM XVA143 (Figures 3A–3C).ber of rolling cells (Figure 2E). At 1 M XVA143, almost
all of the adherent cells exhibited the rolling modality.
At maximally effective XVA143 concentrations of 1 M, Comparison between mAbs to the L I Domain
and 2 I-like Domain for Effect on Adhesivemore cells accumulated and rolled in Ca2/Mg2 than in
Mg2/EGTA (Figure 2B compared to 2E), suggesting that Modality and Global Conformation
Could mAbs also differentially affect firm adhesion asCa2 makes a contribution to rolling interactions in the
XVA143-bound conformation ofL2. No interactions oc- compared to rolling adhesion? TS1/22 Fab to the L I
domain completely inhibited rolling and firm adhesioncurred in Ca2 alone or Ca2 XVA143 (data not shown).
Contrasting results were obtained in assays of binding in both Ca2/Mg2 and Mg2/EGTA (Figure 4). Similarly,
the  I allosteric antagonist BIRT377 completely inhib-of multimeric soluble ICAM-1, which requires high- affin-
ityL2. XVA143 completely abolished binding of ICAM-1 ited rolling and firm adhesion in both Ca2/Mg2 and
Mg2/EGTA (Figure 4), as previously shown for the  Ito LFA-1 in Mn2 and Mg2/EGTA, with no hint of ago-
nism (Figure 2A). allosteric antagonist LFA703 (Salas et al., 2002). TS1/18
(C) L2 K562 cells were resuspended in Buffer A/1 mM Ca2/1 mM Mg2 in the presence of 0 or 1 M XVA143. Cells were infused at 0.4, 0.6,
or 0.8 dyn/cm2 into the flow chamber and the number of bound cells (rolling or firmly adherent) determined with time. Filled and open symbols
are with and without 1 M XVA143, respectively; squares, 0.4 dyn/cm2; circles, 0.6 dyn/cm2; triangles, 0.8 dyn/cm2. Average  s.e.m. of
three experiments.
(D) Freshly isolated human PBMCs resuspended in Buffer A/1 mM Ca2/1 mM Mg2 in the presence of 1 M XVA143, 1 M BIRT377 or the
equivalent amount of DMSO were infused at 0.3 dyn/cm2 and the number of rolling cells was determined at 1 and 2 dyn/cm2. Bars represent
the average  SEM of three independent experiments.
(E) As in (B) except in 2 mM Mg2/1 mM EGTA and the indicated XVA143 concentrations.
Immunity
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Figure 4. Effect of Different LFA-1 Inhibitors on Rolling on
ICAM-1 Substrates
Wild-type L2 K562 cells were treated with 10 g/ml TS1/22 Fab
against the L I domain, 10 g/ml TS1/18 Fab to the 2 I-like domain,
1 M BIRT377, or 1 M XVA143 in 1 mM Ca2/Mg2 or 2 mM Mg2/
1 mM EGTA for 30 min at room temperature, and then accumulated
on an ICAM-1-Fc-coated substrate at 0.3 dyn/cm2. Wall shear
stress was incremented every 10 s and the number of rolling and
firmly adherent cells measured at 1 dyn/cm2. Mean and s.e.m. for
three to four experiments.
2001c). Interestingly, in Ca2/Mg2 TS1/18 Fab in-
creased the number of rolling cells, while it decreased
by a similar amount the number of firmly adherent cells
(Figure 4). Furthermore, whereas in Mg2/EGTA almost
all cells were firmly adherent, TS1/18 Fab resulted in an
almost complete adhesive phase transition, converting
90% of the cells to rolling adhesion.
Although TS1/18 Fab and XVA143 each inhibit firm
adhesion, they differ in other respects. In Ca2/Mg2,
TS1/18 Fab did not increase the total number of adher-
ent cells, whereas XVA143 consistently increased the
total number of adherent cells (Figure 4). Furthermore,
in contrast to XVA143, TS1/18 Fab did not decrease
rolling velocity (data not shown). TS1/18 Fab and
XVA143 were further compared for their effect on activa-
tion epitope exposure (Table 1). Although there was little
Figure 3. XVA143 Dose-Dependent Stabilization of Rolling Adhe- KIM127 or m24 epitope exposure in Ca2/Mg2, pretreat-
sion Mirrors L2 Straightening ment with TS1/18 Fab further reduced epitope exposure.
(A and B) L2 K562 cells were resuspended in Buffer A/1 mM Ca2/ By contrast, in Ca2/Mg2 XVA143 markedly increased
1 mM Mg2 in the presence of 0–1000 nM XVA143. Cells were intro- exposure of both epitopes, and TS1/18 Fab largely and
duced into a flow chamber and allowed to accumulate for 30 s
partially reversed this effect of XVA143 for the KIM127at 0.3 dyn/cm2 onto an ICAM-1-Fc substrate (see Experimental
and m24 epitopes, respectively (Table 1). Expression ofProcedures). Shear was then increased and the number of rolling
both epitopes was increased by Mg2/EGTA and in-cells (A) as well as their rolling velocity (B) was measured at 1, 2,
and 4 dyn/cm2. Average  s.e.m. of three experiments. creased further by Mn2; the increases by Mg2/EGTA
(C) L2 K562 cells in HBS/1 mM Ca2/1 mM Mg2 were incubated and Mn2 were also markedly reversed by TS1/18 Fab
with different concentrations of XVA143. Binding to activation- (Table 1). The results point to two mechanisms for en-
dependent mAbs KIM127 and m24 was detected by flow cytometry.
hancing rolling. TS1/18 inhibits firm adhesion, and thisExposure of the epitopes at 1,000 nM XVA143 appeared maximal,
appears to explain its enhancement of rolling adhesion,because it was equivalent to that in 1 mM Mn2. Average  s.e.m.
because TS1/18 never increased the total number ofof two experiments.
adherent cells. By contrast, XVA143 not only inhibits
firm adhesion but enhances rolling adhesion, as shown
by the increase in total number of adherent cells in Ca2/and other mAbs that bind to the 2 I-like domain are
allosteric inhibitors, since they inhibit ligand binding by Mg2. This enhancement by XVA143 but not TS1/18 Fab
is consistent with induction of the extended conforma-wild-type L2 but notL2 containing an I domain locked
in the high-affinity state with a disulfide bond (Lu et al., tion by XVA143 but not TS1/18 Fab.
L2 Integrin Extension and Leukocyte Rolling
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Table 1. Effect of TS1/18 Fab and XVA143 on Exposure of Activation-Dependent Epitopes
Mouse Fab TS1/18 Fab DMSO XVA143 TS1/18  XVA143
KIM127
Ca2  Mg2 7.3  0.45 5.2  0.5 9.3  0.7 85.8  1.4 33.2  1.8
Mg2  EGTA 27.8  3.7 17.6  0.3 21.6  5.0 87.3  2.8 74.7  3.8
Mn2 48.9  3.3 35.8  2.05 54.2  6.1 75.5  3.6 75.0  3.5
m24
Ca2  Mg2 3.9  1.7 0.2  0.2 5.5  0.9 126.9  0.6 74.2  4.2
Mg2  EGTA 56.3  7.0 18.1  2.8 44.2  1.8 101.3  11.1 102.1  31.5
Mn2 127.0  6.3 83.0  11.6 115.8  8.2 144.1  2.1 146  1.3
Binding of KIM127, m24, and control mouse IgG was determined after incubation with 10 g/ml control mouse Fab or TS1/18 Fab, 1:105
dilution of DMSO or 1 M XVA143 in the presence of the indicated divalent cations. KIM127 and m24 binding was measured with FITC anti-
mouse IgG, Fc specific, and background with control mouse IgG was subtracted. Values are specific mean fluorescence intensity of three to
four independent experiments  S.D.
A Single Mutation in the I Domain Linker, E310A, XVA143-induced rolling (Figure 5B) and KIM127 epitope
exposure, i.e., extension (Figure 5A).Abrogates Both Integrin Activation and L2
Straightening, Resulting in Complete Inhibition
of Rolling and Firm Adhesion Regulation of Integrin Extension by L I and 2 I-like
Interdomain CommunicationMutation of Glu-310 of L to Ala has been shown to
abrogate binding of L2 to ICAM-1 in a static adhesion Overall, the data suggest that communication between
the I domain linker and the I-like domain MIDAS is notassay (Huth et al., 2000). Moreover, this mutant does
not respond to activation by an activating mAb (Huth only crucial for stabilizing the high-affinity conformation
of the I domain, but also regulates the equilibrium be-et al., 2000). Residue L-Glu-310 locates to the linker
that follows the C-terminal 7-helix of the I domain, tween the bent and extended L2 conformers. These
interactions are important in Ca2/Mg2 as well as Mn2,connects to the -propeller domain, and must be nearby
in the 3-dimensional structure to the MIDAS of the 2 and appear to explain the complete absence in Ca2/
Mg2 of rolling interactions in the L-E310A and 2-I-like domain. As proposed (Alonso et al., 2002; Shi-
maoka et al., 2002), Glu-310 has been demonstrated S114A mutants (Figure 5B). In support of the suggestion
that in the absence of interactions between the L linker(Yang et al., 2004b) to function as an intrinsic ligand that
binds to the 2 I-like MIDAS when it is activated, thereby and 2 I-like domains, L2 is locked in a bent conforma-
tion with virtually no equilibration to the extended con-exerting a downward pull on the C-terminal -helix of
the  I domain, and activating its MIDAS. Remarkably, formation, the L-E310A and 2-S114A mutants repro-
ducibly showed in three of three experiments lowerexperiments with K562 transfectants, which expressed
wild-type and mutant L2 at comparable densities as basal binding in Ca2/Mg2 of KIM127 mAb than wild-
type transfectants (Figure 5A).shown with TS2/4 mAb to a constitutively exposed epi-
tope (Figure 5A), showed that the L-E310A mutation To further test the role of L-Glu-310 in interdomain
communication and ligand binding in L2, its influencecompletely abolished rolling adhesion, firm adhesion,
and transient tethering, whether measured in Ca2/Mg2 on ligand-induced exposure of the KIM127 and m24
epitopes was examined. In the presence of control(Figure 5B), Mn2 (Figure 5C), Mg2/EGTA, or low wall
shear stresses of 0.3 dyn/cm2 (data not shown). human IgA complexes with anti-IgA, wild-type L2
transfectants showed significantly more basal binding
of KIM127 mAb than L-E310A 2 transfectants (FigureTreatment with XVA143 Restores Rolling of the
L-E310A 2 Mutant by Inducing Extension of L2 6A), confirming that the E310A mutation pushed the
equilibrium between the bent and extended conforma-Despite the complete absence of adhesive interactions
by the L-E310A mutant, treatment of this mutant with tions toward the bent conformation with no KIM127 epi-
tope exposure. As shown above (Figure 2A), in Ca2/XVA143 restored its ability to support rolling at all wall
shear stresses tested (Figure 5B). The complete lack of Mg2, binding of 20g/ml sICAM-1-Fc complexed with
FITC anti-IgA to wild-type L2 was only moderatelyadhesion of the L-E310A mutant in Mn2 (Figure 5C)
was in excellent agreement with the observation that above background. Coupling of ligand binding to the
KIM127 and m24 epitopes was examined using a highMn2 induced KIM127 epitope exposure in wild-type but
not L-E310A mutant L2 (Figure 5A). Similarly, induc- concentration of 100 g/ml sICAM-1-Fc complexed
with anti-IgA and coincubation with KIM127 or m24 mAbtion of rolling by XVA143 of the L-E310A mutant was
in agreement with induction by XVA143 of KIM127 expo- followed by FITC anti-mouse IgG (Figure 6). For wild-
type L2, multimeric ICAM-1 increased both KIM127sure in the L-E310A mutant as efficiently as with wild-
type L2 (Figure 5A). The S114A mutation in the 2 I-like epitope exposure (p  0.05) and m24 epitope exposure
(p  0.0005), demonstrating ligand binding and its cou-domain has previously been shown to abolish all tested
effects of / I-like allosteric antagonists, suggesting pling to conformational change. By contrast, multimeric
ICAM-1 had no effect on epitope exposure in mutantthat the 2 I-like domain MIDAS is part of the binding
site for these compounds (Shimaoka et al., 2003a). Addi- L-E310A 2 integrins. This experiment confirms that
the equilibria relating ligand binding and exposure oftionally, the 2-S114A mutation completely abolished
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Figure 5. Straightening of L-E310A 2 by XVA143 Restores Rolling Interactions under Flow
(A) K562 cells expressing wt L2, L-E310A 2, or L2-S114A were incubated with 1 M XVA143 or an equivalent concentration of DMSO in
HBS/Ca2  Mg2, or HBS/Mn2. Binding of a control mouse IgG (open curves), the L activation-independent mAb TS2/4, or the 2 activation-
dependent mAbs KIM127 or m24 (closed curves) was detected using flow cytometry. Numbers in the panels are the mean specific fluorescence
intensities (averages of three experiments).
(B) K562 cells expressing wt L2, L-E310A 2, or L2-S114A were incubated in HBS/Ca2  Mg2 with 1 M XVA143 or the equivalent
concentration of DMSO. Cells were allowed to accumulate over an ICAM-1-Fc-coated substrate at 0.3 dyn/cm2, and the flow rate was
increased every 10 s. The number of cells bound, either firmly adherent or rolling, was analyzed at different wall shear stresses.
(C) Same as (B), except in 1 mM Mn2. Data are mean  s.e.m. of three experiments.
KIM127 and m24 epitopes are coupled through L resi- guinal lymph nodes was used to test the effects of
XVA143 on lymphocyte rolling and firm adhesion in vivo.due Glu-310, and does not define whether affinity for
Treatment of wild-type murine lymphocytes with 100ICAM-1, extension, or both are affected. Binding of con-
M XVA143 induced a 50% increase in rolling fractiontrol IgG or TS2/4 (an activation-independent -propeller
compared to vehicle-treated control cells (from 27 mAb) was unchanged by incubation of multimeric
5% to 41  7%) (Figure 7A). This effect of XVA143 wasICAM-1 with wild-type L2 or mutant L-E310A 2 (data
largely eliminated by antibody blockade of L2 functionnot shown).
(Figure 7A). Cooperation with L-selectin was required
for detection of LFA-1-dependent, XVA143-enhanced
XVA143 Treatment Increases the Fraction of Murine lymphocyte rolling, because XVA143-treated lympho-
Lymphocytes that Roll in Lymph Node Microvessels, cytes from L-selectin/ mice did not roll in HEV (data
and Decreases the Speed at which They Roll not shown). Lymphocytes treated with XVA143 rolled at
Physiological lymphocyte rolling in peripheral lymph a markedly slower velocity than cells treated with DMSO
node high endothelial venules (HEV) is mediated primar- vehicle (Figure 7B). Again, this effect of XVA143 was
ily by L-selectin binding to its endothelial ligand, periph- completely reversed by LFA-1 mAb (Figure 7B). The
eral node addressin (PNAd), while the chemokine-trig- effects on lymphocyte rolling velocity were highly signifi-
gered binding of activated L2 to endothelial ICAM-1 cant (Figure 7 legend). These effects were not due to
leads to subsequent firm adhesion (von Andrian and changes in microvascular hemodynamics between
treatment groups (data not shown). Despite the substan-Mackay, 2000). Intravital microscopy (IVM) in mouse in-
L2 Integrin Extension and Leukocyte Rolling
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Figure 6. Induction of Activation-Dependent Epitope Exposure by
Multimeric ICAM-1
K562 cells expressing wt or L2 L-E310A 2 in HBS/Ca2/Mg2
were incubated with ICAM-1-Fc/goat anti-human IgA or human
IgA/goat anti-human IgA in the presence of control IgG, TS2/4, m24,
or KIM127 mAbs. Binding of the mAbs was detected by FITC-anti-
mouse IgG antibody. Binding of control mouse IgG or mAb TS2/4
was unchanged by the presence of multimeric ICAM-1 (not shown).
Data are mean  s.e.m. of three to five experiments. *, p value of
Figure 7. Effects of XVA143 on Intravascular Lymphocyte AdhesionIgA versus ICAM-1-Fc. **, p value of wild-type L2 versus L-
in Lymph Node HEVE310 2.
(A) Rolling fraction of wild-type lymphocytes treated with DMSO,
XVA143, or XVA143 plus anti-L or anti-2 antibody (XVA143mAb).
The different cell samples were sequentially injected intotial reduction in rolling velocity induced by XVA143, the
P-selectin/ recipient mice and their rolling behavior in HEV was
fraction of rolling cells that became firmly adherent was analyzed (n 	 2 mice). Rolling fractions of each lymphocyte sample
markedly reduced from 13  5% to 6  3%. The differ- within the same HEV are identified by symbols connected by straight
ences in the sticking fraction between XVA-treated and lines. Means are shown as horizontal lines. Statistical differences
were evaluated using repeated measurements ANOVA with Bonfer-DMSO-treated lymphocytes were almost statistically
roni correction.significant (p 	 0.059; Figure 7C).
(B) Cumulative velocity curves of rolling cells. Individual rolling ve-
locities are plotted against the percentage of rolling cells moving
Discussion at or below that velocity. The number (n) of cells/venules/mice that
were analyzed for each group is shown in parentheses. Statistical
differences, evaluated using the nonparametric Kruskal-Wallis/2 integrins and L2 especially are best known for sup-
Dunn’s Multiple Comparison test, were as follows: DMSO versusporting firm leukocyte adhesion to endothelium and
XVA143, p  0.001; XVA143 versus XVA143  mAb, p  0.001;transendothelial migration. Nonetheless, as reviewed in
DMSO versus XVA143  mAb, p 
 0.05 (not significant).the Introduction, there is extensive in vivo evidence that
(C) Sticking fraction of lymphocytes treated with DMSO or XVA143
2 integrins includingL2 also contribute to rolling adhe- in lymph node HEV of mice treated as in A (n 	 3 mice). Differences
sion by neutrophils, by affecting the efficiency of accu- between mean values (horizontal lines) did not reach statistical sig-
nificance (p 	 0.059; paired Student’s t test).mulation of rolling cells or the velocity of rolling cells.
How can 2 integrins mediate both rolling and firm adhe-
sion, which can be viewed as phases, analogously to
the liquid and crystalline states, with markedly different firm adhesion, and that an extended conformation of
L2 favors rolling. Furthermore, we demonstrate thatrequirements for receptor-ligand bond formation and
dissociation kinetics? Here, we demonstrate that dis- the overall conformation of L2 and its ability to support
rolling are regulated by interactions between the L Itinct conformational states of L2 regulate rolling and
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and 2 I-like domains, and make the surprising observa- to rolling in vivo may reflect differences in regulation of
LFA-1 between lymphocytes or neutrophils, or differ-tion that an / I-like allosteric integrin antagonist can
inhibit firm adhesion and enhance or induce rolling ad- ences in the concentration and duration of exposure to
activating stimuli such as chemokines in inflamed tis-hesion.
The findings with XVA143 demonstrate that rolling is sues and HEV. Although lower rolling velocity is usually
associated with a higher fraction of cells that becomeinduced by L2 extension in the absence of activation
of high-affinity ligand binding by the I domain. In Ca2/ firmly adherent, XVA143 markedly decreased the frac-
tion that became firmly adherent in HEV. This finding isMg2, XVA143 enhanced the number of cells rolling
through LFA-1 both by increasing the rate of accumula- in agreement with in vitro observations that XVA143
enhances rolling adhesion while blocking firm adhesion.tion of cells in shear flow and hence the total number
of adherent cells, and also by inhibiting firm adhesion The effect on firm adhesion in vivo fell short of statistical
significance; however, we caution that the pharmacoki-through LFA-1. Mg2/EGTA and Mn2 activate firm adhe-
sion through L2. In Mg2/EGTA, XVA143 altered the netics of XVA143 or any other/ I-like allosteric antago-
nist are not yet published, and we do not know if XVA143phenotype from firm adhesion to rolling adhesion. Com-
parison between XVA143-treated cells in Mg2/Ca2 and remained saturating in vivo.
Recently, a “humanized” mAb to the LFA-1 I domainMg2/EGTA shows that Ca2 enhances the stability of
rolling interactions. Ca2 is also important for rolling has been approved by the FDA for treatment of moder-
ate to severe psoriasis (Gordon et al., 2003), and /interactions through4 integrins (de Chateau et al., 2001)
and stabilizes the ADMIDAS of integrin 47 in a confor- I-like allosteric antagonists have been proposed as small
molecule follow-ons to this antibody (Gadek et al., 2002).mation that supports rolling (Chen et al., 2003). Periph-
eral blood lymphocytes failed to mediate rolling on We have shown that a mAb to the L I domain blocks
both firm adhesion and rolling adhesion, whereas /ICAM-1 substrates, consistent with the absence to date
of any publications demonstrating rolling solely through I-like allosteric antagonists of LFA-1 block firm adhesion
while inducing or enhancing rolling adhesion. Because2 integrin-ICAM-1 interactions by peripheral blood leu-
kocytes. However, XVA143 treatment enabled LFA-1 on of the importance of firm adhesion by 2 integrins, this
difference in mechanism of action certainly does notPBL to mediate tethering and rolling in shear flow on
ICAM-1 substrates. Together with our in vivo studies, preclude the therapeutic utility of / I-like allosteric
antagonists; however, it does need to be taken intothis demonstrates that the physiological density of L2
on PBL is sufficient to contribute to rolling, when the account during preclinical and clinical development.
Furthermore, attention should be paid in medicinalconformation of LFA-1 is appropriate.
Direct observations on integrin conformation have chemistry to the difference in potency between blocking
high-affinity ligand binding and inducing rolling adhe-thus far come from crystal, EM, and X-ray scattering
studies on integrins that lack I domains (Adair and Yea- sion, which likely reflects a higher affinity of these antag-
onists for the active conformation of the 2 I-like domain.ger, 2002; Mould et al., 2003a; Takagi et al., 2002, 2003;
Xiong et al., 2001, 2002). Three conformations have been It might be possible to find compounds that differ in
the ratios of the IC50 values for different conformationalrevealed for V3 (Figures 1F–1H), and similar conforma-
tions have been suggested for the I domain-containing states of 2 integrins, as has been demonstrated for
/ I-like competitive antagonists of IIb3 (Bednar etintegrin L2 (Beglova et al., 2002; Takagi et al., 2002)
(Figures 1A–1E). XVA143 induces exposure of the al., 1998).
The TS1/18 Fab has a different mechanism of actionKIM127 epitope in I-EGF module 2, strongly suggesting
conversion ofL2 from a bent to an extended conforma- from XVA143. TS1/18 did not induce rolling by PBL or
enhance adhesion in shear flow to ICAM-1 substrates.tion. In Mn2 or Mg2/EGTA, XVA143 blocked soluble,
multimeric ICAM-1 binding at subnanomolar concentra- However, TS1/18 almost completely switched the adhe-
sive phenotype from firm or mixed adhesion to rollingtions. However, in Ca2/Mg2, XVA143 induced accumu-
lation of rolling cells, a decrease in rolling velocity, and adhesion. Consistent with lack of enhancement of adhe-
siveness by TS1/18 Fab, it did not increase KIM127an increase in KIM127 and m24 epitopes, with half-
maximal effects between 10 and 100 nM. The finding epitope expression. Rather, TS1/18 appears to stabilize
the inactive conformation of the 2 I-like domain, inhib-that XVA143 induces both rolling and integrin extension
as measured by KIM127 epitope exposure, and that iting firm adhesion and enabling rolling adhesion to oc-
cur instead.the dose-response is similar, strongly supports a direct
relationship between the extension of LFA-1 and its en- Overall, the results with XVA143 and TS1/18 Fab sug-
gest that extension of L2 favors adhesion, and thathanced ability to support adhesion in shear flow and
rolling. the conformation of the 2 I-like domain regulates the
affinity of the L I domain and whether it mediates rollingIn vivo data suggest that 2 integrins and LFA-1 on
neutrophils contribute to rolling interactions in inflamed adhesion or firm adhesion. Previous studies on mutant
I domains expressed as isolated L I domains with anvenules (Forlow and Ley, 2001; Forlow et al., 2000; Hen-
derson et al., 2001; Jung et al., 1998; Perry and Granger, artificial transmembrane domain or within intact L2
heterodimers have shown that the wild-type, uncon-1991), whereas LFA-1 on lymphocytes does not contrib-
ute to lymphocyte rolling interactions in uninflamed HEV strained L I domain mediates rolling, whereas the L I
domain locked in the high-affinity conformation medi-(Warnock et al., 1998). The latter result is confirmed by
our findings, but we also demonstrate that when the ates only firm adhesion (Salas et al., 2002). This finding
suggests that XVA143 and TS1/18 each block firm adhe-extended conformation of LFA-1 with a low-affinity I
domain is induced by XVA143, it enhances rolling inter- sion by blocking the conversion of the L I domain to
the high-affinity conformation, although they do so byactions in HEV. Differences in the contribution of LFA-1
L2 Integrin Extension and Leukocyte Rolling
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different mechanisms because XVA143 enhances while ening of the L-E310A mutant as shown by lack of induc-
TS1/18 Fab inhibits induction of the m24 epitope in the2 tion of the KIM127 epitope, and the mutant was com-
I-like domain. In terms of currently understood integrin pletely incapable of interactions in shear flow in Mn2.
conformations, the conformation mediating rolling ap- Mn2 is a strong activator of wild-type L2, inducing
pears to most closely correspond to L2 in an extended opening of the I-like domain as measured with m24 mAb,
conformation with a low-affinity I domain (Figures 1B extension of the integrin as measured with KIM127 mAb,
and 1C), whereas the conformation that mediates firm and firm adhesion. Mn2 activates by binding to the I-like
adhesion appears to most closely correspond to an ex- domain ADMIDAS, as recently demonstrated with the
tended conformation with a high- affinity L I domain 47 integrin (Chen et al., 2003). Together with the posi-
(Figure 1E). tive control of the effect of XVA143 on the L-E310A
The studies with XVA143 and the L-E310A mutation mutant, these results suggest that Mn2 activates ad-
yield insights into communication between the L I and hesiveness of the L I domain through interaction of
2 I-like domains and how it regulates global conforma- L-Glu-310 with the I-like domain. The results further
tion and rolling. The L-Glu-310 residue in the linker demonstrate that the interaction through L-Glu-310 ac-
between the L subunit I and -propeller domains ap- tivated by Mn2 is required for L2 extension as mea-
pears to bind to the 2 I-like MIDAS when it is activated, sured by KIM127 exposure. Some induction of m24 ex-
and through displacement of the C-terminal -helix of pression in the I-like domain by Mn2 is noted in the
the I domain, to transduce activation to the I domain L-E310A mutant, although it is markedly attenuated
MIDAS (Alonso et al., 2002; Shimaoka et al., 2002; Yang compared to wild-type. This is consistent with the ability
et al., 2004b). We found that the L-E310A mutation not of Mn2 to bind to the 2 I-like domain and partially
only blocked firm adhesion, but also completely blocked stabilize localized conformational change, with a partial
rolling adhesion through L2. Expression under basal requirement for linkage through L-Glu-310 to stabilize
conditions of the KIM127 epitope was significantly de- this altered local conformation, and a complete require-
creased, demonstrating coupling of residue L-Glu-310 ment for L-Glu-310 for linkage of local, weak effects of
in the L I domain--propeller linker to a distal site in Mn2 to the L I domain and exposure of the KIM127
the 3-dimensional structure in I-EGF2 in the 2 genu. epitope in 2 I-EGF module 2.
These results suggest that under basal conditions, some In summary, our results show that L2 mediates roll-
equilibration between the bent and extended structures ing when it is in an extended conformation and the L I
occurs, i.e., breathing at the 2 genu, and that this domain is not in a high-affinity state. We demonstrate
breathing is linked to L residue Glu-310, possibly by that equilibration between a bent conformation in which
an interaction of this residue with the 2 I-like domain the KIM127 epitope is buried and an extended confor-
MIDAS. Furthermore, the mutation L-E310A completely mation in which the KIM127 epitope is exposed, i.e.,
abolished increase by soluble, multimeric ICAM-1 of the breathing at the headpiece-tailpiece interface, is impor-
m24 and KIM127 epitopes, demonstrating either that tant for rolling interactions mediated by L2. The inter-
linkage through L-Glu-310 is required for the I domain face between the I domain linker region and the I-like
to have sufficient affinity to bind ligand, or that this domain functions as a switch that can regulate the affin-
linkage is required for ligand binding by the I domain to ity of the L I domain as well as the switchblade-like
be communicated to the 2 I-like domain and the genu. extension of L2. In vivo, L2 is sufficient by itself to
Remarkably, XVA143 rescued the negative effect of support firm adhesion, and can contribute in combina-
the L-E310A mutation on rolling adhesion. Whereas the tion with other adhesion receptors to rolling adhesion.
L-E310A mutation abolished rolling adhesion, addition We demonstrate that a small molecule antagonist can
of XVA143 restored rolling almost to wild-type levels, induce rolling adhesion through L2, and that distinctand induction of the m24 and KIM127 epitopes was conformational states of L2 mediate rolling adhesionsimilar to wild-type. These results further emphasize the
and firm adhesion. This raises the intriguing possibility
importance of the extended integrin conformation for
that in vivo, distinct conformational states of L2 mayrolling adhesion. They suggest that the L-E310A 2 het- also be responsible for supporting rolling and firm adhe-erodimer is in a conformation incapable of supporting
sion. This could occur if intermediate levels of activatingrolling, likely because it is in the bent conformation and
stimuli induced an intermediate conformation of LFA-1does not appreciably equilibrate with the extended con-
that was extended but did not have a fully activated Iformer, as suggested by the lower expression of the
domain, as depicted in Figures 1B and 1C. AnalogousKIM127 epitope on L-E310A 2 than wild-type L2
intermediate states of V3 have been directly observedtransfectants.
(Figure 1G). A novel intermediate conformational stateXVA143 was completely unable to rescue rolling by
of theL I domain has recently been demonstrated struc-the 2 I-like MIDAS mutant S114A, or as previously de-
turally, further emphasizing the complexity of the regula-scribed for this mutant, m24 and KIM127 epitope ex-
tion of L2 (Shimaoka et al., 2003b).pression (Shimaoka et al., 2003a). This supports the
previous conclusion that XVA143 and related / I-like
Experimental Proceduresantagonists utilize as part of their binding site the 2
I-like domain MIDAS. The efficacy of XVA143 with the
Cell Lines, Antibodies, and Small MoleculesL-E310A mutant demonstrates that L-Glu-310 is not K562 cells stably transfected with wild-type L2 were describedan important part of the XVA143 binding site, and is previously (Lu et al., 2001b). L-310A and 2-S114A mutants and
consistent with the model that XVA143 is a mimic of L- L2 K562 transfectants were as described (Shimaoka et al., 2003a).
Glu-310 and inhibits its binding to the 2 I-like MIDAS. Similar L2 surface expression as wild-type was routinely verified
by immunofluorescence flow cytometry. The mouse anti-human LIn contrast to XVA143, Mn2 did not induce straight-
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mAbs TS2/6 (Huang and Springer, 1997) and MHM24 (DAKO; Car- serum albumin (BSA), resuspended at 5  106/ml in Ca2/Mg2-
free HBSS/10 mM Hepes/0.5% BSA (buffer A), and kept at roompinteria, CA), anti-2 Fab TS1/18, and anti-L Fab TS1/22 (Sanchez-
temperature (22C) throughout the experiment. Cells were dilutedMadrid et al., 1982), and matching isotype IgG or Fab controls were
to 5  105/ml in buffer A containing 1 mM Ca2  1 mM Mg2 or 2used to block LFA-1-mediated interactions. A nonbinding mouse
mM Mg2  1 mM EGTA, immediately before infusion in the flowIgG1 (X63) control, anti-human L mAbs, TS1/11, TS1/12, TS2/4, and
chamber using an automated syringe pump. Cells were incubatedanti-2 mAb TS1/18 (all IgG1) were used in immunofluorescent flow
with XVA143 (1 M in DMSO), DMSO alone, or mAbs (as IgG orcytometry (Lu et al., 2001a; Lu and Springer, 1997). Activation-
Fab fragments) at saturating concentrations, for 15 min at roomdependent mAbs KIM127 (Robinson et al., 1992) and m24 (Drans-
temperature. Images were captured using a CCD camera mountedfield and Hogg, 1989; Lu et al., 2001c) were kindly provided by M.
on an inverted microscope with a 10-objective and recorded onRobinson (Celltech, Slough, U.K.) and N. Hogg (Imperial Cancer
Hi-8 videotape.Research Fund, London), respectively. Purified azide-free, low en-
dotoxin anti-mouse CD11a and anti-mouse CD18 (anti-L, M17/4;
Quantification of Interactions under Increasing Shear Forcesanti-2, GAME46; BD Pharmingen, San Diego, CA) were used in
Cells were allowed to accumulate at 0.3 dyn/cm2 for 30 s. Shearintravital microscopy experiments. XVA143 (Welzenbach et al., 2002)
stress was then increased to 0.4 dyn/cm2 and incremented everywas from Dr. Paul Gillespie, Roche, Nutley, NJ. BIRT377 (Last-Bar-
10 s up to 36 dynes/cm2. Rolling velocity at each shear stress wasney et al., 2001) was from Dr. Terence Kelly, Boehringer Ingelheim
calculated from the average distance traveled by rolling cells in 3 s.Pharmaceuticals Inc., Ridgeway, CT. LFA703 (Weitz-Schmidt et al.,
The number of cells interacting for more than 3 s with the coated2001) was from Dr. G. Weitz-Schmidt, Novartis Pharma AG (Basel,
surface was measured at each shear stress. To avoid confusingSwitzerland).
rolling with small amounts of movement due to tether stretching or
measurement error, a velocity of 1.5 m/s, which corresponds to aProduction of Fab
movement of 1/2 cell diameter during the 3 s measurement interval,Fab fragments of mouse IgG (control) and mAbs TS1/22 and TS1/
was the minimum velocity required to define a cell as rolling instead18 were prepared via papain cleavage using the ImmunoPure Fab
of firmly adherent.Preparation Kit (Pierce; Rockford, IL) according to the manufactur-
er’s instructions, and used to block adhesion at 10 or 20 g/ml,
Accumulation of Cells under a Fixed Shear Forcewhich was saturating for the specific Fab.
Cells were prepared as described above, resuspended in buffer A
containing 1 mM Ca2  1 mM Mg2, and as indicated 1 M XVA143.
Peripheral Blood Lymphocytes The cells were infused into the flow chamber, and immediately sub-
Peripheral blood mononuclear cells were prepared by Ficoll- jected to a fixed wall shear stress. The number of cells bound (rolling
Hypaque centrifugation (Ulmer and Flad, 1979). Monocytes were or firm adherent) was determined at different time points.
depleted by diluting mononuclear cells from 43 ml blood in 60 ml
of Hank’s balanced salt solution supplemented with 1% human Statistical Analysis
serum albumin and 20 mM Hepes (pH 7.2) (HHBS-HSA) supple- Data were analyzed when indicated using Student’s unpaired t test.
mented with 1 mM Ca2/Mg2 and plating in three gelatin-coated Values are reported as mean  SEM. Statistical significance was
150 mm cell culture dishes at 37C for 45 min. The nonadherent defined as p  0.05.
lymphocytes were then recovered, pelleted, and resuspended in
HBSS-HSA and used in flow chamber experiments. Intravital Microscopy
WT and L-selectin-deficient (L-selectin/) mice on a mixed C57/
Soluble ICAM-1 Binding Assay B6  129 background were used as lymphocyte donors, and
Cells were harvested, washed with HBS (20 mM HEPES and 150 P-selectin-deficient mice (P-selectin/; also on a C57/B6  129
mM NaCl [pH 7.3]), and incubated with XVA143 (104 to 106 nM in background) were used as recipients in intravital microscopy experi-
DMSO) or DMSO alone (1:1012 to 1:102 dilution) for 15 min at room ments (Weninger et al., 2000). Mice were housed in a specific patho-
temperature (22C). A mixture of 20 g/ml of IC1-5/IgA chimera gen-free and viral antibody-free (SPF/VAF) facility at Harvard Medi-
containing the five Ig domains of human ICAM-1 fused to the Fc cal School. All in vivo procedures complied with NIH guidelines for
the care and use of laboratory animals and were approved by theportion of IgA (ICAM-1-Fc) (Martin et al., 1993) and 25 g/ml of
Committees on Animals of both Harvard Medical School and theaffinity-purified goat anti-human IgA antibody labeled with FITC
CBR Institute for Biomedical Research.(Zymed) was then added to an equal volume (25 l) of cells and
Young adult P-selectin/ mice (6–8 weeks of age) were anaesthe-incubated for 30 min at room temperature. Cells were spun down
tized intraperitoneally with a mixture of ketamine (5 mg/ml) andand resuspended in 2% paraformaldehyde in PBS. Fluorescence
xylazine (1 mg/ml) in physiological saline. P-selectin/ mice werewas detected using flow cytometry.
used as recipients in order to exclude potential contributions of
platelet or endothelial P-selectin to lymphocyte rolling in high endo-Binding of Activation-Dependent mAbs
thelial venules (HEV) (Diacovo et al., 1998). Surgical preparation andin the Presence of sICAM-1
intravital microscopy of the superficial inguinal (subiliac) lymph nodeWt or L-E310A 2 transfected K562 cells were resuspended in
(LN) microvasculature were as described (von Andrian, 1996).HBS/1 mM Ca2  1 mM Mg2. The cell pellet was incubated with
Lymphocytes obtained from pooled peripheral (axillary, brachial,a mixture of 100 g/ml of human IgA or ICAM-1-Fc and 333 g/
and inguinal) and mesenteric lymph nodes were labeled with calceinml of affinity purified goat anti-human IgA antibody for 15 min at
AM (final concentration, 60 M), resuspended in HBSS with 1 mM37C. Thereafter, mouse isotype control IgG, TS2/4, m24, or KIM127
Ca2 and 1 mM Mg2, and treated with either DMSO, 100 M
in HBS/ Ca2 Mg2 was added at 3 g/ml for 30 min at 37C. Cells
XVA143, or 100 M XVA143 and 50 g blocking anti-L or anti-were washed and stained with a FITC-goat anti-mouse IgG for 30
2 antibody at 37C for at least 10 min. Small boluses of controlmin at 4C. After washing, cells were fixed with 2% paraformalde- lymphocytes were then injected intra-arterially and their adhesive
hyde and subjected to immunofluorescence flow cytometry. behavior in LN HEV was recorded. Subsequently, recipient mice
were given intra-arterial injections of XVA143 (10 l of 100 M), and
Cell Adhesion to Immobilized ICAM-1 under Shear Flow XVA143-treated cells were injected and recorded passing through
A chimera containing the five Ig domains of human ICAM-1 fused the same microvessels. In two experiments, recipient mice were
to the Fc portion of IgG (ICAM-1-Fc) at 10 or 60 g/ml in PBS and then treated with either anti-L or anti-2 antibody (50 g) and
20 mM bicarbonate (pH 9.0) (Coating Buffer) for K562 transfectants XVA143 plus antibody-treated cells were injected. Labeled cells
and PBL, respectively, was spotted on a dish previously coated were visualized via epifluorescence (von Andrian and M’Rini, 1998).
with 20l (20g/ml) protein A (Zymed; San Francisco, CA) in Coating Interactions between circulating cells and lymph node HEV were
Buffer and blocked with 2% human serum albumin (HSA). ICAM-1 analyzed from recorded video images. The rolling fraction for each
substrates were assembled as the lower wall in a parallel-wall flow HEV was calculated as the percentage of labeled cells rolling on
chamber and mounted on an inverted phase-contrast microscope the endothelial surface among all labeled cells passing through the
(Lawrence and Springer, 1991). Cells were washed twice with Ca2/ HEV. The sticking fraction was calculated as the percentage of cells
arresting for 
30 s among all rolling cells. Distances traversed byMg2-free HBSS/10 mM Hepes (pH 7.4)/5 mM EDTA/0.5% bovine
L2 Integrin Extension and Leukocyte Rolling
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rolling cells were measured using frame-by-frame video image anal- Fotouhi, N., Gillespie, P., Guthrie, R., Pietranico-Cole, S., and Yun,
W. (1999). Month year. Diaminopropionic acid derivatives. Patentysis with specialized software (VVelocity Spatial Correlation Veloci-
meter, A.R. Preis, Berlin), and then divided by the elapsed time to Cooperation Treaty International Application number WO0021920.
obtain average rolling velocities (vroll). Cumulative velocity curves Gadek, T.R., Burdick, D.J., McDowell, R.S., Stanley, M.S., Marsters,
were as described (Stein et al., 1999). J.C., Jr., Paris, K.J., Oare, D.A., Reynolds, M.E., Ladner, C., Zion-
Means are given SEM. Statistical differences between two data check, K.A., et al. (2002). Generation of an LFA-1 antagonist by
sets were analyzed by paired or unpaired two-tailed Student’s t the transfer of the ICAM-1 immunoregulatory epitope to a small
tests, as indicated. Differences between multiple data sets assum- molecule. Science 295, 1086–1089.
ing Gaussian distributions (e.g., rolling fraction) were analyzed by Gordon, K.B., Papp, K.A., Hamilton, T.K., Walicke, P.A., Dummer,
repeated measurements ANOVA with Bonferroni correction. For W., Li, N., Bresnahan, B.W., and Menter, A. (2003). Efalizumab for
multiple data sets with non-Gaussian distributions (e.g., rolling ve- patients with moderate to severe plaque psoriasis: a randomized
locities), the nonparametric Kruskal-Wallis/Dunn’s Multiple Compar- controlled trial. JAMA 290, 3073–3080.
ison test was used.
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